Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canephron-N
- Development stage
- Phase 3
- Lead developer
- Bionorica
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Canephron-N is a phytotherapeutic (herbal) medicine developed by Bionorica. It is a standardized combination of three active herbal ingredients: common centaury (Centaurium erythraea), lovage root (Levisticum officinale), and rosemary leaves (Rosmarinus officinalis). It is approved and widely used for the supportive treatment and prevention of inflammatory diseases of the urinary tract, such as acute and chronic cystitis, pyelonephritis, and for the prevention of urinary stones (urolithiasis). Canephron-N exhibits multi-target pharmacological properties, including anti-inflammatory, spasmolytic, diuretic, anti-adhesive, and anti-nociceptive effects. In clinical trials, it has demonstrated non-inferiority to standard antibiotic therapy (such as fosfomycin) in treating acute lower uncomplicated urinary tract infections (uUTIs), helping to reduce antibiotic use and support antimicrobial stewardship.
- Brand names
- CanephronCanephron ForteCanephron NCanephron Uno
- Other names
- Centaurii herba + Levistici radix + Rosmarini foliumcentaury + lovage + rosemarycentaury herb + lovage root + rosemary leaf
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)ALOX5 (Arachidonate 5-lipoxygenase)mPGES-2 (Microsomal prostaglandin E synthase-2)
Beyond the preview
Go deeper on Canephron-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canephron-N.